Please assess the completion status of the following clinical trial:

Trial Title: Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Infants \> 2.5 kg birth weight~* Immediate cry~* No neonatal IMCI danger signs~* Not planning to travel away during entire the study period (birth-102 days)~Exclusion Criteria:~* High-risk newborns will be excluded, as well as newborns requiring hospitalization~* Birth weight below 2.5 kg~* Cry \>2 minutes~* With any neonatal IMNCI danger signs~* Residence \>30 km from study site~* Family is planning to be absent during the birth - 102 day study period.~* A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family - e.g. several early infant deaths, household member on chemotherapy) will render the newborn ineligible for the study.

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 24 Hours
- Healthy Volunteers: t

Study Arms:
- mOPV1- Arm A (Type: EXPERIMENTAL): Arm A will be administered a second dose of mOPV1 seven days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at day 79.
- mOPV1- Arm B (Type: EXPERIMENTAL): Arm B will be administered a second dose of mOPV1 fourteen days after after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 86 days.
- mOPV1-Arm C (Type: EXPERIMENTAL): Arm C will receive the second dose of mOPV1 thirty days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 102 days.
- Arm D- bOPV1,3 (Type: EXPERIMENTAL): Arm D will be administered a second dose of bOPV1,3 thirty days after the 42 day bOPV1,3 index dose.Second dose of tOPV2 will be given at day 102.

Based on this trial design, predict the completion outcome and termination type (if applicable).